NCT04993352View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of HLX04-O in Subjects With wAMD

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

July 7, 2022

Study Completion Date

March 13, 2023

Conditions
Age Related Macular Degeneration
Interventions
DRUG

recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection

0.05mL (12.5mg/0.5mL/vial) HLX-04-O solution at a 4-week interval for intravitreal injection

Trial Locations (1)

Unknown

XuZhou Central Hospital, Xuzhou

All Listed Sponsors
lead

Shanghai Henlius Biotech

INDUSTRY